All rights reserved. The company says its main candidate EYP001, in … Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, European Union (EU) Early Stage Companies, Sofinnova Investments Portfolio Companies. ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public). Experienced Biotechnology and Investment Banking Executive Joins Executive Team. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications. afloyer@newcap.fr. The Company’s most advanced compound, EYP001, is a small molecule (non-Bile Acid FXR agonist) therapeutic in Phase II clinical development for the treatment of Chronic Hepatitis B and NASH. Lyon Investor Relations: Clinical trials set up and management in compliance with the timelines, budget, & regulations. Oct. 2018 - present: CPM ENYO PHARMA (Lyon – France) Hepatitis B, Phase I (The Netherlands; 11 patients) & Phase II (The Netherlands, Australia, Poland, Thailand; 200 patients) trials. FXR agonists have gained attention as potential therapeutic agents in hepatobiliary and metabolic diseases. ENYO Pharma announced that it has completed a €40 million Series B round of financing from US and European investors. SEE WEBSITE. Powered by Madgex Job Board Software, ENYO Pharma Announces Multiple EYP001 Data Presentations At AASLD Conference, Enyo Pharma Announces Move to New Corporate Headquarters, ENYO Pharma Announces New CFO And Provides Clinical Pipeline Update, ENYO Pharma Announces the Successful Completion of Phase Ib with Its FXR Agonist EYP001 and the Start of Phase II Studies in Two Indications, NASH and HBV, ENYO Pharma Raises €40 Million in Series B Fundraising, LYONBIOPOLE Will Unite Leading French Biotech Actors at the 2018 BIO International Convention, ENYO Pharma Strengthens Its Leadership Team with a NASH Expert and Announces that its Phase Ib Trial in Chronic HBV Infected Patients is on Track with its FXR Agonist EYP001, Charles River Announces Success of Integrated Discovery Project With ENYO Pharma, ENYO Pharma Opens a New Subsidiary in Australia as a New Managing Center for Clinical Trials, Enyo Pharma Announces Successful Completion Of EYP001 First In Man Phase I Study, Enyo Pharma Strengthens Its Business Team To Support International Growth, Poxel SAS Announces Phase 1 Initiation Of EYP001 For The Treatment Of Chronic Hepatitis B Virus Infection By Licensing Partner Enyo Pharma, Enyo Pharma Announces Successful Initiation Of The Phase 1 Clinical Programme With EYP001, Its Lead Candidate For The Treatment Of Chronic Hepatitis B Virus Infection, Enyo Pharma Receives A €2.5 Million Grant From EU Under The Horizon2020/SME Instrument Phase II Programme For Its Project MIMESIS, Enyo Pharma Strengthens Its Management Team To Support Its Strategy Of International Growth, Enyo Pharma Announces Closing Of A €22 Million Funding Round, Enyo Pharma Strengthens Its Arsenal Of Hepatitis B Potential Therapies, EDELRIS Announce Exclusive License Agreement With Enyo Pharma, POXEL Announces Patent Access Agreement With Enyo Pharma. “During the conference we will also be holding a symposium with high level, key opinion leaders to discuss ENYO’s research and our innovative approach to potentially cure Hepatitis B," continued Dr. Vonderscher. ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules. The Company’s most advanced compound, EYP001, is a small molecule (non-Bile Acid FXR agonist) therapeutic in Phase II clinical development for the treatment of Chronic Hepatitis B and NASH. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. ENYO’s founders are a mix of virus-host protein interactions experts from the French Infectiology Research Center in Lyon and pharmaceutical industry executives with an impressive track record in drug development. For more information on ENYO and EYP001, please visit http://www.enyopharma.com/. ENYO Pharma will be at the Hynes Convention Center to present four posters and hold an oral presentation about its lead candidate EYP001 and its preclinical and clinical results: In vitro characterization of EYP001 a novel, potent and selective FXR agonist entering phase 2 clinical trials in chronic hepatitis B.

How Many Times Did Kobe Go To The Finals, Scary Pop Up Videos, Johnson And Johnson Placement Salary, Top 100 Selling Drugs 2019, Armada - Asal Kau Bahagia Mp3, Abandoned Places Near Pittsburgh, Shayne Topp Henry Danger, Matilda The Musical Tour 2020, Ship Channel Constructors, Ace Of Cakes Episodes Youtube,